fbpx
April 27, 2024

New cancer clinical trial: Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Published on: July 28, 2017 at 12:00PM
Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage II Anal Canal Cancer AJCC v6 and v7;   Stage III Anal Canal Cancer AJCC v6 and v7;   Stage IIIA Anal Canal Cancer AJCC v6 and v7;   Stage IIIB Anal Canal Cancer AJCC v6 and v7
Intervention:   Biological: Nivolumab
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting – verified July 2017
http://ift.tt/2ucbT9j

%d bloggers like this: